A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
Status:
COMPLETED
Trial end date:
2025-10-08
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to investigate the effect of bosentan, a moderate Cytochrome P450 (CYP) 3A inducer on the single dose pharmacokinetics of nerandomilast.